Walleye Capital
TARS icon

Walleye Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Walleye Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Sell
15,184
-25,089
-62% -$1.75M ﹤0.01% 2019
2025
Q4 		$3.3M Buy
40,273
+30,790
+325% +$2.3M 0.01% 1464
2025
Q3 		$564K Sell
9,483
-435
-4% -$21.4K ﹤0.01% 2515
2025
Q2 		$402K Buy
+9,918
New +$446K ﹤0.01% 2818
2024
Q3 		– Sell
-75,588
Closed -$2.05M – 5852
2024
Q2 		$2.05M Sell
75,588
-196,910
-72% -$6.62M ﹤0.01% 2072
2024
Q1 		$9.91M Buy
+272,498
New +$8.01M 0.02% 833

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's TARS Position: Q1 2026 in Review

Walleye Capital reduced its Tarsus Pharmaceuticals (TARS) stake by 62% in Q1 2026, selling an estimated $1.75M and leaving 15,184 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Walleye Capital first reported a position in TARS in Q1 2024 and has held it in 6 quarters since. The position peaked at $9.91M in Q1 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Walleye Capital held 15,184 shares of Tarsus Pharmaceuticals worth $1.07M as of Q1 2026.
  • Walleye Capital sold 25,089 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $1.75M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2019 holding.
  • Walleye Capital first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Walleye Capital's Tarsus Pharmaceuticals position peaked at $9.91M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.